Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiken Biomedical CoTPE:7780 +1.51%22 Forward PE Ratio is 23.76 as of Aug. 01, 2026. GuruFocus rates TPE:7780 with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 747 Consumer Packaged Goods companies, Daiken Biomedical Co ranks worse than 78.98% on this metric.
Daiken Biomedical Co (TPE:7780) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Daiken Biomedical Co Forward PE Ratio Related Terms
Daiken Biomedical Co Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Daiken Biomedical Co's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiken Biomedical Co Forward PE Ratio Chart
Daiken Biomedical Co Annual Data
Trend
2025-12
Forward PE Ratio
23.62
Daiken Biomedical Co Quarterly Data
2025-12
2026-03
Forward PE Ratio
23.62
31.12
TPE:7780 vs KHC, GIS: Forward PE Ratio Comparison
For the Packaged Foods subindustry, Daiken Biomedical Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiken Biomedical Co Forward PE Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Daiken Biomedical Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Daiken Biomedical Co's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Daiken Biomedical Co (TPE:7780) has a Forward PE Ratio of 23.76 as of Aug. 01, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Daiken Biomedical Co and its competitors. According to the industry distribution chart, Daiken Biomedical Co ranks #590 out of 747 companies in the Consumer Packaged Goods industry, placing it in the top 79%.
Is Daiken Biomedical Co's Forward PE Ratio too high?
Daiken Biomedical Co's current Forward PE Ratio is 23.76. The Consumer Packaged Goods industry median Forward PE Ratio is 14.61. Daiken Biomedical Co's value of 23.76 is 62.6% above this industry median. Based on the distribution chart, Daiken Biomedical Co ranks #590 out of 747 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Daiken Biomedical Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Daiken Biomedical Co's Forward PE Ratio compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Daiken Biomedical Co ranks #590 out of 747 companies for Forward PE Ratio. This places Daiken Biomedical Co in the lower half of its industry. The industry median Forward PE Ratio is 14.61. Daiken Biomedical Co's value of 23.76 is 62.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Consumer Packaged Goods company?
The median Forward PE Ratio among Consumer Packaged Goods companies is 14.61, based on 747 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiken Biomedical Co's current Forward PE Ratio of 23.76 is 62.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Daiken Biomedical Co and its competitors. For the Consumer Packaged Goods industry, the median Forward PE Ratio is 14.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiken Biomedical Co's current Forward PE Ratio is 23.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Biomedical Co stock overvalued right now?
Daiken Biomedical Co (TPE:7780) has a current Forward PE Ratio of 23.76. The current Forward PE Ratio is 23.76 and 62.6% above the Consumer Packaged Goods industry median of 14.61. Daiken Biomedical Co's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Daiken Biomedical Co (TPE:7780), the current Forward PE Ratio is 23.76 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Daiken Biomedical Co Ltd is engaged in Research, development, and sales of health food. Its products include fish oil capsules, collagen powder, collagen drinks, natto capsules, and mint leaf capsules. The companies reportable operating segment consists solely of the e-commerce division.
22GF Score
Get the complete analysis for TPE:7780
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7780 has been successfully added to your 
